Literature DB >> 21818112

Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.

F X Gruber, T Ernst, K Porkka, R A Engh, I Mikkola, J Maier, T Lange, A Hochhaus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21818112     DOI： 10.1038/leu.2011.187

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.

Authors:  Constance Baer; Wolfgang Kern; Sarah Koch; Niroshan Nadarajah; Sonja Schindela; Manja Meggendorfer; Claudia Haferlach; Torsten Haferlach
Journal:  Haematologica       Date:  2016-04-21       Impact factor: 9.941

2.  Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.

Authors:  Filip Razga; Tomas Jurcek; Daniela Zackova; Dana Dvorakova; Martina Toskova; Ivana Jeziskova; Jiri Mayer; Zdenek Racil
Journal:  Mol Diagn Ther       Date:  2012-08-01       Impact factor: 4.074

3.  BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.

Authors:  A Slupianek; R Falinski; P Znojek; T Stoklosa; S Flis; V Doneddu; D Pytel; E Synowiec; J Blasiak; A Bellacosa; T Skorski
Journal:  Leukemia       Date:  2012-10-09       Impact factor: 11.528

Review 4.  Molecular biology as a tool for the treatment of cancer.

Authors:  Carla de Castro Sant' Anna; Alberto Gomes Ferreira Junior; Paulo Soares; Fabricio Tuji; Eric Paschoal; Luiz Cláudio Chaves; Rommel Rodriguez Burbano
Journal:  Clin Exp Med       Date:  2018-07-13       Impact factor: 3.984

5.  BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.

Authors:  T P Hughes; G Saglio; A Quintás-Cardama; M J Mauro; D-W Kim; J H Lipton; M B Bradley-Garelik; J Ukropec; A Hochhaus
Journal:  Leukemia       Date:  2015-06-29       Impact factor: 11.528

6.  BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance.

Authors:  W T Parker; A L Yeoman; B A Jamison; D T Yeung; H S Scott; T P Hughes; S Branford
Journal:  Br J Cancer       Date:  2013-06-25       Impact factor: 7.640

7.  Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.

Authors:  Simona Soverini; Caterina De Benedittis; Katerina Machova Polakova; Jana Linhartova; Fausto Castagnetti; Gabriele Gugliotta; Cristina Papayannidis; Manuela Mancini; Hana Klamova; Marzia Salvucci; Monica Crugnola; Alessandra Iurlo; Francesco Albano; Domenico Russo; Gianantonio Rosti; Michele Cavo; Michele Baccarani; Giovanni Martinelli
Journal:  Oncotarget       Date:  2016-04-19

8.  Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.

Authors:  R Kastner; A Zopf; S Preuner; J Pröll; N Niklas; P Foskett; P Valent; T Lion; C Gabriel
Journal:  Eur J Cancer       Date:  2013-12-20       Impact factor: 9.162

Review 9.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113

10.  Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.

Authors:  Martin Culen; Marek Borsky; Veronika Nemethova; Filip Razga; Jiri Smejkal; Tomas Jurcek; Dana Dvorakova; Daniela Zackova; Barbora Weinbergerova; Lukas Semerad; Irina Sadovnik; Gregor Eisenwort; Harald Herrmann; Peter Valent; Jiri Mayer; Zdenek Racil
Journal:  Oncotarget       Date:  2016-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.